Go to the list of all blogs
Abhoy Sarkar's Avatar
published in Blogs
Apr 13, 2021

Bristol-Myers (BMY, $63.09) got a rating boost from Truist

Bristol-Myers Squibb  got a rating upgrade from Truist, on optimism about drug pipeline.

Truist analyst Gregg Gilbert boosted rating on the pharmaceutical company to buy from hold. Gilbert also raised his price target to $74 a share from $66. 

“We launched on U.S. major [pharmaceuticals] in October with an overall bullish view on the group, but we started with a hold rating on BMY pending greater visibility on key late-stage pipeline assets,” Gilbert wrote in a commentary. Since then, BMY has received regulatory approval for Abecma (ide-cel) and Breyanzi (liso-cel), and announced positive top-line Phase 3 results for deucravacitinib (TYK2 inhibitor) and relatlimab (LAG-3 inhibitor), Gilbert mentioned.

Gilbert cited pipeline progress coupled with results from detailed pipeline analysis as factors behind the rating boost.

Related Ticker: BMY

Momentum Indicator for BMY turns negative, indicating new downward trend

BMY saw its Momentum Indicator move below the 0 level on April 08, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on April 03, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

BMY moved below its 50-day moving average on April 10, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BMY crossed bearishly below the 50-day moving average on April 12, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BMY entered a downward trend on April 16, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 322 cases, the price rose further within the following month. The odds of a continued upward trend are .

BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.642) is normal, around the industry mean (5.632). P/E Ratio (13.728) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.404) is also within normal values, averaging (3.004). Dividend Yield (0.044) settles around the average of (0.164) among similar stocks. P/S Ratio (2.447) is also within normal values, averaging (3.643).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -3%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -2%. RHHBF experienced the highest price growth at 2%, while MIRA experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was -71% and the average quarterly volume growth was -8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 53
Price Growth Rating: 78
SMR Rating: 64
Profit Risk Rating: 73
Seasonality Score: 10 (-100 ... +100)
Related Portfolios: BIOTECHNOLOGY SECTOR
View a ticker or compare two or three
BMYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
34100
Web
https://www.bms.com
Ad is loading...
Discover the dynamic world of cryptocurrency trading with Tickeron's AI analysis. Capitalize on bullish and bearish patterns in Origin Protocol (OGN.X), with gains up to 27.80%. Stay ahead with Tickeron's real-time insights and make informed trading decisions. #CryptoTrading #AIAnalysis #OriginProtocol #InvestSmart
#latest#popular#patterns#artificial_intelligence#trading#technical_analysis
Dive into the world of trading excellence with our Best AI Robot of the week! In a market characterized by growth, the key to maximizing profits lies not only in mainstream large-cap stocks but also in exploring opportunities across different market segments.
This article delves into the performance of AI trading robots, specifically those utilizing the "Swing trader: Long-Short Equity Strategy (TA&FA)." These bots showcased their prowess by delivering a notable +4.98% gain while engaging in MRNA trades over the previous week. Beyond mere statistics, we explore the technical indicators and recent earnings report of MRNA to shed light on the underlying dynamics influencing the stock.
Artificial intelligence (AI) trading bots have become powerful tools for investors seeking active trading opportunities. In a recent analysis conducted on the "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" platform, AI trading bots exhibited impressive performance, generating a noteworthy +4.81% gain while actively trading Shopify (SHOP) over the course of the previous week.
In the dynamic world of finance, strategic asset acquisition is a game-changer. Recently, a group of stocks within this domain has been in the spotlight, showcasing notable performances and intriguing patterns. This article delves into the recent movements of these stocks, focusing on key indicators, market capitalization, notable price events, and volume dynamics.
Urology companies, comprising EDAP (EDAP), Teleflex (TFX), and UroGen Pharma (URGN), have shown a remarkable +6.67% increase in performance over the last week. In this analysis, we delve into various indicators and metrics to better understand the current landscape and individual trajectories within this thematic sector.
In the ever-evolving landscape of financial markets, Artificial Intelligence (AI) trading robots have emerged as potent tools for investors seeking an edge. The recent performance of the AI trading robots accessible through "Swing Trader, Popular Stocks: Short Bias Strategy (TA&FA)" has caught the attention of market participants. Notably, these bots generated an impressive +10.22% gain in a week, with a focus on trading TSM (Taiwan Semiconductor Manufacturing Company).
In the fast-paced world of stock trading, artificial intelligence (AI) has become a game-changer, with trading robots demonstrating impressive results. The "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)" platform recently showcased the effectiveness of its bots, generating a notable +7.86% gain while actively trading AMD over the past week.
​​​​​​​Aluminum companies have witnessed a remarkable surge in performance, with a collective increase of +8.75% over the past week. In this analysis, we delve into the dynamics of this surge, focusing on key indicators and individual stock movements. The tickers in focus are CENX, AA, KALU, and CSTM.
​​​​​​​Propane gas companies, represented by tickers NGL, SGU, and SPH, have exhibited a remarkable +8.22% increase in performance over the past week. This surge is substantiated by various technical indicators, fostering a positive outlook for investors. In this analysis, we delve into key indicators, market capitalization, notable price movements, and volume fluctuations to provide a comprehensive understanding of the current landscape.
In the fast-paced world of AI trading, algorithms powered by sophisticated technical analysis tools are making waves. The "Swing trader: Top High-Volatility Stocks v.2 (TA)" bots have proven their mettle, securing a remarkable +6.02% gain in a week of trading AVGO.
Artificial intelligence (AI) trading robots have become an integral part of the market landscape. One such example is the "Swing Trader, Popular Stocks: Short Bias Strategy (TA&FA)" bot, which showcased impressive results with a +5.54% gain while trading LRCX over the past week. In this article, we delve into the technical analysis of LRCX, examining its recent earnings report and broader industry trends.
The drilling industry has recently experienced a commendable upswing, with a substantial 8.22% surge in performance over the past week. In this article, we will dissect the current dynamics of key players in this sector, focusing on prominent tickers such as DO, RIG, HP, NBR, NR, PDS, and PTEN.
In the realm of AI-driven trading, the "Swing Trader: ETFs for Growing Industries (TA)" platform recently showcased impressive results, with its trading bots generating a noteworthy +5.09% gain while actively trading TQQQ over the past week. As we delve into the intricacies of these AI trading strategies, let's dissect the recent earning results and market indicators to better understand the driving forces behind their success.
In the fast-paced world of AI-driven trading, the utilization of sophisticated algorithms and technical analysis tools is becoming increasingly prevalent. One notable example is the Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA), which demonstrated its prowess by generating a commendable +5.02% gain while trading NVDA over the past week. Let's delve into the technical indicators and earnings results to gain a comprehensive understanding of NVDA's current market standing.
In the fast-paced realm of biotech and pharmaceuticals, a group of stocks, including giants like Johnson & Johnson (JNJ), Amgen (AMGN), Pfizer (PFE), Astex Pharmaceuticals (ATXS), AnaptysBio (ANAB), and Zymeworks (ZYME), witnessed a noteworthy 8.55% surge in performance over the past week. However, a closer look at various indicators suggests caution, signaling a potential downturn.
In the dynamic landscape of the energy sector, onshore oil exploration companies have recently experienced a remarkable upswing, with a notable 7.13% increase in performance over the past week. This surge has captivated market attention, and several key indicators point towards a sustained positive outlook. In this analysis, we delve into the financial health, market dynamics, and recent events surrounding prominent tickers in this domain - PXD, CNQ, PDS, PTEN, and FANG.
Tickeron's Quant team is delighted to introduce our latest AI-powered robot designed for trading small-cap stocks, employing a distinctive fundamental stock analysis algorithm. This algorithm, renowned for its blend of in-depth analysis and intuitive signal-following capabilities, is well-suited for both novice and seasoned traders.
In the dynamic world of stock trading, the utilization of AI trading robots has become increasingly prevalent. One such example is the "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," which showcased its prowess by yielding a remarkable +4.98% gain while trading ZIM over the previous week. As we delve into the intricacies of ZIM's recent performance, let's analyze the earnings results, market indicators, and industry trends that shape the narrative.
In the ever-evolving landscape of financial markets, artificial intelligence (AI) trading bots have emerged as powerful tools, providing investors with automated strategies to navigate the complexities of stock trading. In this analysis, we delve into the recent performance of AI trading robots, specifically those accessible through "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," which demonstrated a remarkable +4.67% gain while trading MRVL over the previous week.